Physician profile
Tamar Shafran
NPI 1306167135
$865.54
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $12.77 · 2021: $59.27 · 2022: $241 · 2023: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $234.95 | 2019-2020 | |
| Horizon Therapeutics Plc | $159.67 | 2022-2023 | Tepezza |
| Abbvie INC. | $146.01 | 2022-2023 | Xen Glaucoma Treatment System, Durysta |
| Allergan, INC. | $94.40 | 2021-2022 | |
| Alcon Vision LLC | $74.90 | 2022-2023 | Clareon, Argos |
| Ocular Therapeutix, INC. | $54.93 | 2023 | Dextenza |
| Biotissue Holdings INC. | $24.99 | 2023 | |
| New World Medical,INC. | $17.92 | 2022 | |
| Bausch & Lomb Americas INC. | $15.76 | 2022 | |
| Rayner Intraocular Lenses Limited | $15.63 | 2022 | |
| Omeros Corporation | $13.88 | 2019 | |
| Sight Sciences, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamar Shafran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.